Pancreatic Cancer Stage IV Clinical Trial
Official title:
Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone. Cabiralizumab is an antibody (a type of protein) that binds to a molecule called CSF-1r. CSF-1r is a molecule present on different types of cells in your immune system that controls parts of your immune system. Blocking CSF-lr could potentially stop the cancer cells which it appears on from escaping the immune system, which could then act to kill the cancer cells. Nivolumab is an anti-PD-1 antibody that boost the body's immune system. It works by attaching to and blocking a molecule on white blood cells called PD-1. PD-1 is a protein that is present on different types of cells in your immune system and controls parts of your immune system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from shutting down the immune system, thus allowing immune cells to recognize and destroy cancer cells. Gemcitabine is currently used to treat advanced or metastasized (spread) pancreatic cancer. It is used in patients whose disease cannot be removed by surgery and who have already been treated with other chemotherapy
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03252808 -
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.
|
Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06017284 -
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT04674956 -
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03412799 -
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT04181645 -
SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
|
N/A | |
| Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
| Recruiting |
NCT04150042 -
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
|
Phase 1 | |
| Recruiting |
NCT04628806 -
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
|
||
| Recruiting |
NCT02981641 -
IORT Versus CCRT for Pancreatic Cancer
|
N/A | |
| Completed |
NCT04953962 -
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05254171 -
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03236883 -
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT04406831 -
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
|
||
| No longer available |
NCT04137822 -
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
|